Is Egrifta (Tesamorelin) Legal in Illinois?

Federal Legal Status: FDA Approval and Scheduling

Tesamorelin carries full FDA approval. This single fact separates it from peptides sold in legal gray areas.

The FDA first approved Egrifta (tesamorelin) on November 10, 2010, under NDA 022505, for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. [1] A reformulated version, Egrifta SV (2 mg/vial), received supplemental approval in 2019, improving stability and reducing injection volume. [2] Because tesamorelin has gone through the full NDA pathway, it is not a research chemical, not an unapproved peptide, and not subject to the regulatory uncertainty that surrounds compounds like BPC-157 or TB-500.

Controlled Substance Act Classification

Tesamorelin is not listed in any schedule of the Controlled Substances Act (CSA). [3] A clinician in Illinois does not need a DEA-issued controlled substance registration to prescribe it. A standard state medical license with prescriptive authority is sufficient.

FDA-Approved Indication: What the Label Says

The Egrifta SV prescribing information states the drug is indicated "for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy." [2] Off-label use (for example, in non-HIV adults seeking body composition changes or growth hormone secretagogue effects) is not prohibited by federal law, but it does shift the evidence burden onto the prescriber and changes the insurance reimbursement picture significantly.

Clinical Trial Data Supporting Approval

The approval rested on two Phase 3 trials. In the LPHS-2 trial (N=404), tesamorelin 2 mg daily reduced visceral adipose tissue (VAT) by a mean of 18% versus 5% for placebo at 26 weeks (P<0.0001). [4] A second 26-week extension showed that patients who continued tesamorelin maintained VAT reduction while those switched to placebo regained fat. [4] These data formed the primary basis for the FDA's risk-benefit determination and underpin why the drug holds a legitimate approval rather than a conditional or accelerated one.

Illinois State Legal Framework

Illinois does not impose any state-level restriction on tesamorelin beyond the standard prescription drug rules that apply to every legend drug sold in the state.

The Illinois Pharmacy Practice Act (225 ILCS 85) requires that all prescription-only medications be dispensed pursuant to a valid prescription from a licensed practitioner. [5] Tesamorelin qualifies as a prescription-only drug under federal law (21 U.S.C. 353(b)), so that federal classification automatically triggers the Illinois requirement. No additional Illinois statute singles out tesamorelin or growth hormone-related peptides for special scheduling. [5]

Illinois Medical Practice Act and Prescriber Authority

Under the Illinois Medical Practice Act (225 ILCS 60), any physician licensed by the Illinois Department of Financial and Professional Regulation (IDFPR) may prescribe FDA-approved drugs within the scope of their practice. [6] Nurse practitioners and physician assistants with full prescriptive authority under their respective Illinois practice acts may also prescribe Egrifta, provided they do so within their supervised or collaborative practice agreements where those remain applicable.

Off-label prescribing is legal under both federal and Illinois state law. The American Medical Association's policy states that "physicians may prescribe legally available drugs for uses not listed in the FDA's labeling when such uses are based on sound medical evidence." [7] An Illinois physician choosing to prescribe tesamorelin off-label bears the professional responsibility of documenting medical necessity and informing the patient.

Illinois Department of Financial and Professional Regulation Oversight

The IDFPR licenses and disciplines both prescribers and pharmacists in Illinois. A prescriber who writes for tesamorelin outside of any rational clinical basis risks professional discipline for unprofessional conduct under 225 ILCS 60/22, but the drug itself is not subject to any Illinois-specific prohibition. [6] Patients should confirm their prescriber holds an active, unrestricted IDFPR license before proceeding.

Compounded Tesamorelin: 503A, 503B, and the FDA Bulk Drug List

This is the area where the legal picture becomes more complicated. Branded Egrifta is legal and FDA-approved. Compounded tesamorelin occupies a narrower and more regulated space.

What the FDA Bulk Drug List Means

The FDA Drug Shortages and Compounding staff maintains lists of bulk drug substances that may be used by 503A (traditional) and 503B (outsourcing facility) compounders. A compound using a bulk API that appears on neither list, and that has an FDA-approved equivalent (like Egrifta), faces significant regulatory pressure. [8] The FDA's current 503B bulks list does not include tesamorelin as a standalone approved bulk substance, which means 503B outsourcing facilities must weigh whether compounding it is consistent with federal law when an FDA-approved version exists and is not in shortage. [8]

Under 21 U.S.C. 503A, a traditional compounding pharmacy may prepare a drug that is "essentially a copy" of an FDA-approved drug only under limited circumstances, such as documented patient need for a different strength or route not commercially available. [9] A patient who simply wants a cheaper version of Egrifta does not automatically meet that bar.

Illinois Board of Pharmacy Rules on Compounding

The Illinois Board of Pharmacy, operating under IDFPR authority, follows the federal USP 795 (non-sterile) and USP 797 (sterile) compounding standards. Tesamorelin is a sterile injectable, so any Illinois-licensed 503A pharmacy compounding it must comply with USP 797 clean-room and beyond-use dating requirements. [10] Illinois does not maintain a separate state-level bulk drug list that would expand on the federal framework.

Practical Implication

If a telehealth or direct-to-consumer peptide clinic offers you compounded tesamorelin at a steep discount compared with branded Egrifta, ask the following questions before accepting a prescription. Is the compounding pharmacy 503A or 503B registered? Can they document the USP 797 compliance record? Does the prescriber have a documented clinical rationale for using the compounded form instead of the commercially available product? Without satisfactory answers, you may be receiving a product whose legal standing is uncertain under both federal and Illinois law.

How to Get Egrifta (Tesamorelin) in Illinois: Step-by-Step

Getting a legitimate tesamorelin prescription in Illinois follows the same pathway as any other FDA-approved specialty drug.

Step 1: Confirm You Meet the Approved Indication (or Have a Documented Off-Label Rationale)

The FDA-approved indication is excess abdominal fat in HIV-infected adults with lipodystrophy. HIV status, antiretroviral therapy, and imaging or anthropometric confirmation of lipodystrophy are the documented clinical criteria. [2] If you are seeking tesamorelin for non-HIV reasons, your prescriber must document why the off-label use is clinically justified, which requires lab work, imaging, or other objective findings.

Step 2: Find a Qualified Illinois Prescriber

Any Illinois-licensed MD, DO, NP, or PA with prescriptive authority may write this prescription. Endocrinologists, infectious disease specialists, and anti-aging or hormone therapy specialists are common prescribers. Telehealth platforms operating legally in Illinois, meaning those that have established a valid patient-provider relationship before prescribing, may also issue the prescription. Illinois follows the same telehealth prescribing rules established under the Ryan Haight Online Pharmacy Consumer Protection Act for scheduled substances, but because tesamorelin is not scheduled, the primary requirement is simply that a legitimate patient-provider relationship exists. [11]

Step 3: Fill the Prescription at a Licensed Illinois Pharmacy

Major specialty pharmacies (such as Accredo or CVS Specialty) fill Egrifta and handle the prior authorization process with insurers. Patients may also use a licensed compounding pharmacy if the prescriber specifies a compounded formulation with documented clinical justification (see Section 3 above).

Step 4: Manage Insurance and Patient Assistance

Egrifta SV is covered by most major insurance plans for on-label use in HIV lipodystrophy, subject to prior authorization. Medicare Part D covers it under the specialty tier. For patients without coverage, Theratechnologies operates a patient assistance program. [12] The average wholesale price without assistance runs approximately $8,000 to $12,000 per month, making reimbursement a practical priority for most patients.

Safety Profile and Prescribing Considerations

Tesamorelin works by binding to pituitary GHRH receptors and stimulating endogenous growth hormone (GH) release, which in turn raises IGF-1 levels. [2] Because it affects the GH/IGF-1 axis, prescribers must monitor for fluid retention, glucose dysregulation, and potential tumor promotion in patients with a history of malignancy.

Key Contraindications

The prescribing information lists active malignancy, disruption of the hypothalamic-pituitary axis (such as hypophysitis or prior cranial irradiation), and pregnancy as contraindications. [2] Patients with pre-existing type 2 diabetes or impaired glucose tolerance require baseline and follow-up HbA1c monitoring, because GH elevation can worsen insulin sensitivity. [4]

Monitoring Parameters

Standard monitoring includes fasting glucose or HbA1c at baseline and every 6 months, IGF-1 levels at baseline and 1 month after initiation (with dose adjustment if IGF-1 exceeds the upper limit of normal for age), and clinical assessment of fluid retention. [2] The package insert specifically notes that "patients who have evidence of neoplastic disease should not be treated with Egrifta." [2]

Drug Interactions

No major pharmacokinetic drug-drug interactions have been identified. Tesamorelin may alter cortisol levels measured by some assays because GH stimulates 11-beta-hydroxysteroid dehydrogenase, which could affect steroid replacement dosing in patients on hydrocortisone or fludrocortisone. Prescribers managing adrenal insufficiency alongside lipodystrophy should account for this interaction. [2]

Off-Label Use in Non-HIV Patients: What the Evidence Shows

Tesamorelin's approval covers HIV lipodystrophy only, but its mechanism as a GHRH analog has drawn interest for other applications, including general visceral obesity, age-related GH decline, and cognitive function in older adults.

Visceral Fat in Non-HIV Obesity

A Phase 2 trial published in the Journal of Clinical Endocrinology and Metabolism (N=155, non-HIV adults with abdominal obesity) showed tesamorelin 2 mg daily reduced VAT by 15% versus 2% placebo over 26 weeks (P<0.001). [13] No regulatory submission for this indication has been made, so off-label use in this population remains the only legal route in the United States.

Cognitive Function in Older Adults

Researchers at Vanderbilt University published a randomized controlled trial (N=152, adults aged 60 or older with mild cognitive impairment or normal cognition) showing that tesamorelin 1 mg daily improved cognition scores on the Modified Rey Auditory Verbal Learning Test at 20 weeks versus placebo (P<0.05). [14] This research is preliminary, and no guidelines from the Endocrine Society or the American Academy of Neurology currently recommend tesamorelin for cognitive indications. [15]

Risk-Benefit Discussion for Off-Label Use

Off-label prescribing of tesamorelin in non-HIV patients raises cost, monitoring burden, and the absence of long-term safety data in metabolically healthy individuals. Prescribers considering this route should document the clinical rationale, review the contraindications above, and set a predefined treatment duration with objective endpoints before initiating therapy. The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency in adults notes that GHRH analogs have not been studied long-term outside their approved populations, and their use should proceed with appropriate clinical oversight. [15]

Telehealth Prescribing of Tesamorelin in Illinois

Illinois allows telehealth prescribing of non-scheduled drugs without the same restrictions that apply to Schedule II-IV controlled substances under the Ryan Haight Act. [11] Because tesamorelin is unscheduled, a licensed Illinois telehealth provider who completes a valid clinical evaluation (which includes a review of medical history, current medications, relevant lab work, and an interactive real-time visit) may legally prescribe Egrifta or order the patient to a specialty pharmacy.

The Illinois Telehealth Act (Public Act 101-0542) requires that telehealth services meet the same standard of care as in-person services. [16] A telehealth prescriber who skips the clinical workup, ignores contraindications, or prescribes tesamorelin without confirming the appropriate indication is exposing themselves to IDFPR disciplinary action regardless of whether the prescription itself is technically legal.

Patients should also verify that any telehealth platform they use employs prescribers with active Illinois licenses. Out-of-state prescribers may not prescribe for Illinois patients unless they hold an Illinois license or fall within a temporary authorization during a declared public health emergency.

Summary of the Legal Framework at a Glance

Tesamorelin is legal in Illinois under the following conditions: a licensed Illinois prescriber writes the prescription, the patient fills it at a licensed pharmacy, and the prescriber has documented a legitimate clinical rationale. Compounded tesamorelin exists in a narrower legal space governed by FDA 503A/503B rules and USP 797 sterile compounding standards. No Illinois-specific law creates additional barriers beyond the standard prescription drug pathway.

The drug is not a controlled substance. It does not require DEA registration to prescribe. It does not appear on any Illinois restricted substance list. The legal risk, such as it is, arises primarily from using unlicensed vendors, receiving compounded product from non-compliant pharmacies, or working with out-of-state prescribers who lack Illinois licensure.

Patients with HIV lipodystrophy in Illinois should start with an infectious disease specialist or endocrinologist, confirm insurance coverage before filling, and request the branded Egrifta SV unless there is a documented clinical reason to use a compounded alternative. IGF-1 should be measured at baseline and one month after initiating 2 mg daily dosing.